Stocksigma LogoStocksigma Logo

Cohance Lifesciences Q2 FY27 Financial and Operational Performance Overview

Cohance Lifesciences reported Q2 FY27 revenue of INR 4,767 Mn, down 14.2% YoY but recovering 12.9% QoQ

Cohance Lifesciences Q2 FY27 Financial and Operational Performance Overview

Cohance Lifesciences Ltd 路 Investor Presentation 路 07 Nov 2026, 10:25 pm

Cohance Lifesciences Q2 FY27 Financial and Operational Performance Overview Cohance Lifesciences reported Q2 FY27 revenue of INR 4,767 Mn, down 14.2% YoY but recovering 12.9% QoQ. Adjusted EBITDA stood at INR 458 Mn with margins improving sequentially to 9.6% from 2.2% in Q1. Adjusted PAT turned positive at INR 75 Mn. H1 FY27 revenue fell 18.6% YoY to INR 8,989 Mn. API+ grew 5% YoY in Q2, while Sapala surged 33.6% YoY. Management expects stronger H2 performance driven by Pharma CDMO reload deliveries, API+ resilience, and higher capacity utilisation. Net cash stood at INR 666 Mn as of 30th Sep'26.

Original exchange filing (PDF)

More announcements from Cohance Lifesciences Ltd

All Cohance Lifesciences Ltd announcements